BIOMAT Database Logo BIOMAT Database Logo

A UK survey of tamoxifen prescribing and oestrogen receptor status. 2002

K S Madhavan, and P A Murray
Department of Clinical Oncology, Essex County Hospital, Lexden, Colchester CO3 3NB, UK.

UI MeSH Term Description Entries

Related Publications

K S Madhavan, and P A Murray
Tamoxifen therapy, oestrogen receptor status, and postmenopausal breast cancer.
April 1985, Lancet (London, England),
K S Madhavan, and P A Murray
Oestrogen-receptor status in management of breast cancer in UK.
July 1998, Lancet (London, England),
K S Madhavan, and P A Murray
Tamoxifen, screening and new oestrogen receptor modulators.
June 2001, Best practice & research. Clinical obstetrics & gynaecology,
K S Madhavan, and P A Murray
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
May 2006, Annals of oncology : official journal of the European Society for Medical Oncology,
K S Madhavan, and P A Murray
Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells.
January 1994, Biochemical pharmacology,
K S Madhavan, and P A Murray
Tamoxifen and oestrogen replacement.
July 1990, Lancet (London, England),
K S Madhavan, and P A Murray
Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor.
March 1975, European journal of cancer,
K S Madhavan, and P A Murray
Oestrogen replacement in Turner syndrome: current prescribing practice in the UK.
November 2009, Clinical endocrinology,
K S Madhavan, and P A Murray
Tamoxifen: oestrogen or anti-oestrogen in bone?
May 1995, QJM : monthly journal of the Association of Physicians,
K S Madhavan, and P A Murray
BASP1 interacts with oestrogen receptor α and modifies the tamoxifen response.
May 2017, Cell death & disease,
Copied contents to your clipboard!